The landscape of BRAF transcript and protein variants in human cancer

Andrea Marranci, Zhijie Jiang, Marianna Vitiello, Elena Guzzolino, Laura Comelli, Samanta Sarti, Simone Lubrano, Cinzia Franchin, Ileabett Echevarría-Vargas, Andrea Tuccoli, Alberto Mercatanti, Monica Evangelista, Paolo Sportoletti, Giorgio Cozza, Ettore Luzi, Enrico Capobianco, Jessie Villanueva, Giorgio Arrigoni, Giovanni Signore, Silvia RocchiccioliLetizia Pitto, Nicholas Tsinoremas, Laura Poliseno

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: The BRAF protein kinase is widely studied as a cancer driver and therapeutic target. However, the regulation of its expression is not completely understood. Results: Taking advantage of the RNA-seq data of more than 4800 patients belonging to 9 different cancer types, we show that BRAF mRNA exists as a pool of 3 isoforms (reference BRAF, BRAF-X1, and BRAF-X2) that differ in the last part of their coding sequences, as well as in the length (BRAF-ref: 76 nt; BRAF-X1 and BRAF-X2: up to 7 kb) and in the sequence of their 3'UTRs. The expression levels of BRAF-ref and BRAF-X1/X2 are inversely correlated, while the most prevalent among the three isoforms varies from cancer type to cancer type. In melanoma cells, the X1 isoform is expressed at the highest level in both therapy-naïve cells and cells with acquired resistance to vemurafenib driven by BRAF gene amplification or expression of the Δ[3-10] splicing variant. In addition to the BRAF-ref protein, the BRAF-X1 protein (the full length as well as the Δ[3-10] variant) is also translated. The expression levels of the BRAF-ref and BRAF-X1 proteins are similar, and together they account for BRAF functional activities. In contrast, the endogenous BRAF-X2 protein is hard to detect because the C-terminal domain is selectively recognized by the ubiquitin-proteasome pathway and targeted for degradation. Conclusions: By shedding light on the repertoire of BRAF mRNA and protein variants, and on the complex regulation of their expression, our work paves the way to a deeper understanding of a crucially important player in human cancer and to a more informed development of new therapeutic strategies.

Original languageEnglish (US)
Article number85
JournalMolecular Cancer
Volume16
Issue number1
DOIs
StatePublished - Apr 28 2017

Fingerprint

Protein Isoforms
Neoplasms
Proteins
Proto-Oncogene Proteins B-raf
Messenger RNA
Gene Amplification
3' Untranslated Regions
Proteasome Endopeptidase Complex
Cell- and Tissue-Based Therapy
Ubiquitin
Protein Kinases
Melanoma
RNA
Gene Expression
Therapeutics
PLX4032

Keywords

  • BRAF
  • Exon-spanning reads
  • Melanoma
  • Protein variants
  • RNA-sequencing
  • Transcript variants

ASJC Scopus subject areas

  • Molecular Medicine
  • Oncology
  • Cancer Research

Cite this

Marranci, A., Jiang, Z., Vitiello, M., Guzzolino, E., Comelli, L., Sarti, S., ... Poliseno, L. (2017). The landscape of BRAF transcript and protein variants in human cancer. Molecular Cancer, 16(1), [85]. https://doi.org/10.1186/s12943-017-0645-4

The landscape of BRAF transcript and protein variants in human cancer. / Marranci, Andrea; Jiang, Zhijie; Vitiello, Marianna; Guzzolino, Elena; Comelli, Laura; Sarti, Samanta; Lubrano, Simone; Franchin, Cinzia; Echevarría-Vargas, Ileabett; Tuccoli, Andrea; Mercatanti, Alberto; Evangelista, Monica; Sportoletti, Paolo; Cozza, Giorgio; Luzi, Ettore; Capobianco, Enrico; Villanueva, Jessie; Arrigoni, Giorgio; Signore, Giovanni; Rocchiccioli, Silvia; Pitto, Letizia; Tsinoremas, Nicholas; Poliseno, Laura.

In: Molecular Cancer, Vol. 16, No. 1, 85, 28.04.2017.

Research output: Contribution to journalArticle

Marranci, A, Jiang, Z, Vitiello, M, Guzzolino, E, Comelli, L, Sarti, S, Lubrano, S, Franchin, C, Echevarría-Vargas, I, Tuccoli, A, Mercatanti, A, Evangelista, M, Sportoletti, P, Cozza, G, Luzi, E, Capobianco, E, Villanueva, J, Arrigoni, G, Signore, G, Rocchiccioli, S, Pitto, L, Tsinoremas, N & Poliseno, L 2017, 'The landscape of BRAF transcript and protein variants in human cancer', Molecular Cancer, vol. 16, no. 1, 85. https://doi.org/10.1186/s12943-017-0645-4
Marranci A, Jiang Z, Vitiello M, Guzzolino E, Comelli L, Sarti S et al. The landscape of BRAF transcript and protein variants in human cancer. Molecular Cancer. 2017 Apr 28;16(1). 85. https://doi.org/10.1186/s12943-017-0645-4
Marranci, Andrea ; Jiang, Zhijie ; Vitiello, Marianna ; Guzzolino, Elena ; Comelli, Laura ; Sarti, Samanta ; Lubrano, Simone ; Franchin, Cinzia ; Echevarría-Vargas, Ileabett ; Tuccoli, Andrea ; Mercatanti, Alberto ; Evangelista, Monica ; Sportoletti, Paolo ; Cozza, Giorgio ; Luzi, Ettore ; Capobianco, Enrico ; Villanueva, Jessie ; Arrigoni, Giorgio ; Signore, Giovanni ; Rocchiccioli, Silvia ; Pitto, Letizia ; Tsinoremas, Nicholas ; Poliseno, Laura. / The landscape of BRAF transcript and protein variants in human cancer. In: Molecular Cancer. 2017 ; Vol. 16, No. 1.
@article{60bae403204647cc8d5e6d271626b2db,
title = "The landscape of BRAF transcript and protein variants in human cancer",
abstract = "Background: The BRAF protein kinase is widely studied as a cancer driver and therapeutic target. However, the regulation of its expression is not completely understood. Results: Taking advantage of the RNA-seq data of more than 4800 patients belonging to 9 different cancer types, we show that BRAF mRNA exists as a pool of 3 isoforms (reference BRAF, BRAF-X1, and BRAF-X2) that differ in the last part of their coding sequences, as well as in the length (BRAF-ref: 76 nt; BRAF-X1 and BRAF-X2: up to 7 kb) and in the sequence of their 3'UTRs. The expression levels of BRAF-ref and BRAF-X1/X2 are inversely correlated, while the most prevalent among the three isoforms varies from cancer type to cancer type. In melanoma cells, the X1 isoform is expressed at the highest level in both therapy-na{\"i}ve cells and cells with acquired resistance to vemurafenib driven by BRAF gene amplification or expression of the Δ[3-10] splicing variant. In addition to the BRAF-ref protein, the BRAF-X1 protein (the full length as well as the Δ[3-10] variant) is also translated. The expression levels of the BRAF-ref and BRAF-X1 proteins are similar, and together they account for BRAF functional activities. In contrast, the endogenous BRAF-X2 protein is hard to detect because the C-terminal domain is selectively recognized by the ubiquitin-proteasome pathway and targeted for degradation. Conclusions: By shedding light on the repertoire of BRAF mRNA and protein variants, and on the complex regulation of their expression, our work paves the way to a deeper understanding of a crucially important player in human cancer and to a more informed development of new therapeutic strategies.",
keywords = "BRAF, Exon-spanning reads, Melanoma, Protein variants, RNA-sequencing, Transcript variants",
author = "Andrea Marranci and Zhijie Jiang and Marianna Vitiello and Elena Guzzolino and Laura Comelli and Samanta Sarti and Simone Lubrano and Cinzia Franchin and Ileabett Echevarr{\'i}a-Vargas and Andrea Tuccoli and Alberto Mercatanti and Monica Evangelista and Paolo Sportoletti and Giorgio Cozza and Ettore Luzi and Enrico Capobianco and Jessie Villanueva and Giorgio Arrigoni and Giovanni Signore and Silvia Rocchiccioli and Letizia Pitto and Nicholas Tsinoremas and Laura Poliseno",
year = "2017",
month = "4",
day = "28",
doi = "10.1186/s12943-017-0645-4",
language = "English (US)",
volume = "16",
journal = "Molecular Cancer",
issn = "1476-4598",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - The landscape of BRAF transcript and protein variants in human cancer

AU - Marranci, Andrea

AU - Jiang, Zhijie

AU - Vitiello, Marianna

AU - Guzzolino, Elena

AU - Comelli, Laura

AU - Sarti, Samanta

AU - Lubrano, Simone

AU - Franchin, Cinzia

AU - Echevarría-Vargas, Ileabett

AU - Tuccoli, Andrea

AU - Mercatanti, Alberto

AU - Evangelista, Monica

AU - Sportoletti, Paolo

AU - Cozza, Giorgio

AU - Luzi, Ettore

AU - Capobianco, Enrico

AU - Villanueva, Jessie

AU - Arrigoni, Giorgio

AU - Signore, Giovanni

AU - Rocchiccioli, Silvia

AU - Pitto, Letizia

AU - Tsinoremas, Nicholas

AU - Poliseno, Laura

PY - 2017/4/28

Y1 - 2017/4/28

N2 - Background: The BRAF protein kinase is widely studied as a cancer driver and therapeutic target. However, the regulation of its expression is not completely understood. Results: Taking advantage of the RNA-seq data of more than 4800 patients belonging to 9 different cancer types, we show that BRAF mRNA exists as a pool of 3 isoforms (reference BRAF, BRAF-X1, and BRAF-X2) that differ in the last part of their coding sequences, as well as in the length (BRAF-ref: 76 nt; BRAF-X1 and BRAF-X2: up to 7 kb) and in the sequence of their 3'UTRs. The expression levels of BRAF-ref and BRAF-X1/X2 are inversely correlated, while the most prevalent among the three isoforms varies from cancer type to cancer type. In melanoma cells, the X1 isoform is expressed at the highest level in both therapy-naïve cells and cells with acquired resistance to vemurafenib driven by BRAF gene amplification or expression of the Δ[3-10] splicing variant. In addition to the BRAF-ref protein, the BRAF-X1 protein (the full length as well as the Δ[3-10] variant) is also translated. The expression levels of the BRAF-ref and BRAF-X1 proteins are similar, and together they account for BRAF functional activities. In contrast, the endogenous BRAF-X2 protein is hard to detect because the C-terminal domain is selectively recognized by the ubiquitin-proteasome pathway and targeted for degradation. Conclusions: By shedding light on the repertoire of BRAF mRNA and protein variants, and on the complex regulation of their expression, our work paves the way to a deeper understanding of a crucially important player in human cancer and to a more informed development of new therapeutic strategies.

AB - Background: The BRAF protein kinase is widely studied as a cancer driver and therapeutic target. However, the regulation of its expression is not completely understood. Results: Taking advantage of the RNA-seq data of more than 4800 patients belonging to 9 different cancer types, we show that BRAF mRNA exists as a pool of 3 isoforms (reference BRAF, BRAF-X1, and BRAF-X2) that differ in the last part of their coding sequences, as well as in the length (BRAF-ref: 76 nt; BRAF-X1 and BRAF-X2: up to 7 kb) and in the sequence of their 3'UTRs. The expression levels of BRAF-ref and BRAF-X1/X2 are inversely correlated, while the most prevalent among the three isoforms varies from cancer type to cancer type. In melanoma cells, the X1 isoform is expressed at the highest level in both therapy-naïve cells and cells with acquired resistance to vemurafenib driven by BRAF gene amplification or expression of the Δ[3-10] splicing variant. In addition to the BRAF-ref protein, the BRAF-X1 protein (the full length as well as the Δ[3-10] variant) is also translated. The expression levels of the BRAF-ref and BRAF-X1 proteins are similar, and together they account for BRAF functional activities. In contrast, the endogenous BRAF-X2 protein is hard to detect because the C-terminal domain is selectively recognized by the ubiquitin-proteasome pathway and targeted for degradation. Conclusions: By shedding light on the repertoire of BRAF mRNA and protein variants, and on the complex regulation of their expression, our work paves the way to a deeper understanding of a crucially important player in human cancer and to a more informed development of new therapeutic strategies.

KW - BRAF

KW - Exon-spanning reads

KW - Melanoma

KW - Protein variants

KW - RNA-sequencing

KW - Transcript variants

UR - http://www.scopus.com/inward/record.url?scp=85018436573&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018436573&partnerID=8YFLogxK

U2 - 10.1186/s12943-017-0645-4

DO - 10.1186/s12943-017-0645-4

M3 - Article

C2 - 28454577

AN - SCOPUS:85018436573

VL - 16

JO - Molecular Cancer

JF - Molecular Cancer

SN - 1476-4598

IS - 1

M1 - 85

ER -